Bank of New York Mellon Corp grew its stake in shares of NantHealth Inc (NYSE:NH) by 194.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,849 shares of the company’s stock after acquiring an additional 29,639 shares during the quarter. Bank of New York Mellon Corp’s holdings in NantHealth were worth $190,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. TIAA CREF Investment Management LLC increased its holdings in shares of NantHealth by 68.6% during the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after acquiring an additional 8,217 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of NantHealth by 366.4% during the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock valued at $125,000 after acquiring an additional 19,694 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of NantHealth during the second quarter valued at about $245,000. Renaissance Technologies LLC acquired a new position in shares of NantHealth during the first quarter valued at about $457,000. Finally, National Planning Corp acquired a new position in shares of NantHealth during the second quarter valued at about $473,000.
TRADEMARK VIOLATION NOTICE: “NantHealth Inc (NH) Stake Boosted by Bank of New York Mellon Corp” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/11/05/nanthealth-inc-nh-stake-boosted-by-bank-of-new-york-mellon-corp.html.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of NantHealth from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. BidaskClub downgraded shares of NantHealth from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Jefferies Group LLC restated a “buy” rating and set a $5.00 price objective on shares of NantHealth in a report on Thursday, September 28th. Finally, Canaccord Genuity restated a “buy” rating and set a $6.00 price objective (down previously from $8.00) on shares of NantHealth in a report on Monday, August 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. NantHealth has an average rating of “Buy” and a consensus target price of $8.30.
NantHealth Inc (NYSE:NH) opened at $3.29 on Friday. NantHealth Inc has a fifty-two week low of $2.60 and a fifty-two week high of $13.12.
NantHealth (NYSE:NH) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.32). NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. The business had revenue of $26.23 million during the quarter, compared to analyst estimates of $31.28 million. During the same quarter last year, the company posted ($0.15) EPS. NantHealth’s quarterly revenue was down 16.7% compared to the same quarter last year.
In related news, COO Ronald Allen Louks sold 26,820 shares of the stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $4.28, for a total value of $114,789.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.